The leading donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury. Used by more than 30,000 patients at over 150 U.S. transplant centers
The leading donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury. Used by more than 30,000 patients at over 150 U.S. transplant centers
Multi-modality surveillance combining dd-cfDNA, gene expression profiling, and machine learning driven prognostic assessment.
CareDx is continuing to innovate with new products like HistoMap and UroMap and post-market approval studies